SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science reports 92% fall in Q4 consolidated net profit

10 May 2019 Evaluate

Strides Pharma Science has reported results for the fourth quarter and year ended March 31, 2019. 

The company has reported a fall of 87.01% in its net profit at Rs 98.82 crore for the quarter ended March 31, 2019 as compared to Rs 760.54 crore for the same quarter in the previous year. However, total income of the company increased by 11.97% at Rs 490.97 crore for quarter under review as compared to Rs 438.48 crore for the quarter ended March 31, 2018.

On consolidated basis, the company has reported fall of 92.26% in its net profit at Rs 44.70 crore for the quarter ended March 31, 2019 as compared to Rs 577.72 crore for the corresponding quarter in the FY18. However, total consolidated income of the company rose 24.65% at Rs 854.29 crore for quarter under review as compared to Rs 685.32 crore for the same quarter ended previous year.

For the year ended March 31, 2019, the company has posted a fall of 87.62% in its net profit at Rs 110.37 crore as compared to Rs 891.60 crore for the previous year. However, total income of company increased marginally by 1.61% at Rs 1,652.05 crore for year under review as compared to Rs 1,625.81 crore for year ended March 31, 2018.

For the year ended March 31, 2019, on the consolidated basis, the company has posted fall of 51.80% in its net profit at Rs 329.87 crore as compared to Rs 684.39 crore for the previous year. However, total income of company increased by 4.65% at Rs 3057.11 crore for year under review as compared to Rs 2921.41 crore for year ended March 31, 2018.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×